CVRx, Inc.(CVRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CVRX CVRx, Inc.

Trading 01-08 11:37:07 EST

14.08

-0.11

-0.78%

High14.10	Low13.83	Vol19.09K
Open14.06	D1 Closing14.19	Amplitude1.87%
Mkt Cap341.63M	Tradable Cap206.62M	Total Shares24.26M
T/O268.15K	T/O Rate0.13%	Tradable Shares14.67M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CVRX","market":"US","secType":"STK","nameCN":"CVRx, Inc.","latestPrice":14.08,"timestamp":1736354211854,"preClose":14.19,"halted":0,"volume":19090,"delay":0,"floatShares":14674571,"shares":24263663,"eps":-2.709454,"marketStatus":"Trading","change":-0.11,"latestTime":"01-08 11:37:07 EST","open":14.06,"high":14.1,"low":13.834,"amount":268152.20933,"amplitude":0.018746,"askPrice":14.12,"askSize":84,"bidPrice":14.04,"bidSize":160,"shortable":3,"etf":0,"ttmEps":-2.709454,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1736370000000},"marketStatusCode":2,"adr":0,"listingDate":1625025600000,"exchange":"NASDAQ","adjPreClose":14.19,"preHourTrading":{"tag":"盘前","latestPrice":13.95,"preClose":14.19,"latestTime":"09:28 EST","volume":1030,"amount":14221.37068,"timestamp":1736346480062},"postHourTrading":{"tag":"盘后","latestPrice":14.19,"preClose":14.19,"latestTime":"16:01 EST","volume":6539,"amount":92788.41,"timestamp":1736283705760},"volumeRatio":0.428852,"impliedVol":0.9686,"impliedVolPercentile":0.7937},"requestUrl":"/m/hq/s/CVRX","defaultTab":"news","newsList":[{"id":"2495540535","title":"Institutions own 39% of CVRx, Inc. (NASDAQ:CVRX) shares but private equity firms control 39% of the company","url":"https://stock-news.laohu8.com/highlight/detail?id=2495540535","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495540535?lang=en_us&edition=fundamental","pubTime":"2024-12-30 20:50","pubTimestamp":1735563032,"startTime":"0","endTime":"0","summary":"Significant control over CVRx by private equity firms implies that the general public has more power to influence management and governance-related decisions. A total of 8 investors have a majority stake in the company with 53% ownership. A look at the shareholders of CVRx, Inc.  can tell us which group is most powerful. With 39% stake, private equity firms possess the maximum shares in the company. In other words, the group stands to gain the most  from their investment into the company.Meanwhile, institutions make up 39% of the company’s shareholders. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time.In the chart below, we zoom in on the different ownership groups of CVRx.NasdaqGS:CVRX Earnings and Revenue Growth December 30th 2024. While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/institutions-own-39-cvrx-inc-125032412.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NDAQ","CVRX","QLD","BK4585","PSQ","BK4539","BK4588","LU2210150020.SGD","NVIW.SI","BK4112","TSYW.SI","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4082","SQQQ","IE00BKPKM429.USD","USAW.SI","NQmain","USJW.SI","LU2210149790.SGD","TQQQ",".IXIC","MNQmain","QID","IE00B64PRP62.GBP","LU2095319765.USD"],"gpt_icon":1},{"id":"2491569407","title":"Strong Growth Outlook for CVRx: Buy Rating Supported by Strategic Adjustments and Market Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2491569407","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491569407?lang=en_us&edition=fundamental","pubTime":"2024-12-16 22:25","pubTimestamp":1734359112,"startTime":"0","endTime":"0","summary":"Lake Street analyst Frank Takkinen reiterated a Buy rating on CVRx (CVRX – Research Report) today and set a price target of $19.00. Frank Takkinen ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/strong-growth-outlook-for-cvrx-buy-rating-supported-by-strategic-adjustments-and-market-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/strong-growth-outlook-for-cvrx-buy-rating-supported-by-strategic-adjustments-and-market-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CVRX"],"gpt_icon":0},{"id":"2490712991","title":"CVRx Inc : Canaccord Genuity Raises Target Price to $22 From $17","url":"https://stock-news.laohu8.com/highlight/detail?id=2490712991","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490712991?lang=en_us&edition=fundamental","pubTime":"2024-12-09 15:47","pubTimestamp":1733730447,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nFWN3NA0IP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4082","CVRX"],"gpt_icon":0},{"id":"2488940382","title":"CVRx management to meet with Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2488940382","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488940382?lang=en_us&edition=fundamental","pubTime":"2024-12-04 00:05","pubTimestamp":1733241917,"startTime":"0","endTime":"0","summary":"Meeting to be held in Minneapolis on December 12 hosted by Lake Street. Published first on TheFly – the ultimate source for real-time, market-movin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cvrx-management-to-meet-with-lake-street-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cvrx-management-to-meet-with-lake-street-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","BK4539","CVRX"],"gpt_icon":0},{"id":"2487559898","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2487559898","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487559898?lang=en_us&edition=fundamental","pubTime":"2024-11-29 20:54","pubTimestamp":1732884874,"startTime":"0","endTime":"0","summary":"Applied Therapeutics (APLT) shares slumped 73% pre-bell Friday, extending Wednesday's slide.CVRx (CVRX) shares dropped 20% following a muted session.KalVista Pharmaceuticals (KALV) shares were down 9% after a 1.1% increase in the previous session.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KALV","BK4082","LU0320765992.SGD","BK4139","CVRX","LU0109394709.USD","BK4539","LU0889565916.HKD","APLT"],"gpt_icon":0},{"id":"2486358232","title":"CVRx Insiders May Regret Not Buying More, Market Cap Hits US$377m","url":"https://stock-news.laohu8.com/highlight/detail?id=2486358232","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486358232?lang=en_us&edition=fundamental","pubTime":"2024-11-28 03:23","pubTimestamp":1732735397,"startTime":"0","endTime":"0","summary":"Insiders who bought CVRx, Inc. ( NASDAQ:CVRX ) stock in the last 12 months were richly rewarded last week. The...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-cvrx/cvrx/news/cvrx-insiders-may-regret-not-buying-more-market-cap-hits-us3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4082","CVRX","BK4539"],"gpt_icon":0},{"id":"2486003899","title":"Cvrx (CVRX) Declined Due To Turbulence In The Direct Sales Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2486003899","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486003899?lang=en_us&edition=fundamental","pubTime":"2024-11-26 21:31","pubTimestamp":1732627861,"startTime":"0","endTime":"0","summary":"Mairs & Power, an investment advisor, released the “Mairs & Power Small Cap” third quarter 2024 investor letter.A copy of the letter can be downloaded here. Non-technology equities were the market leaders in the first quarter, but mega-cap technology companies made a strong comeback in the second quarter. The market expanded again in the most recent quarter as interest-rate and economically sensitive areas like Utilities, Industrials, and small-cap stocks outperformed. Year-to-date the fund is up 8.95% slightly underperforming the 9.33% return for the S&P Small Cap 600 Total Return  benchmark and the 10.90% return for its peer group, the Morningstar U.S. Fund Small Blend. In addition, please check the fund’s top five holdings to know its best picks in 2024.\"Also detracting from performance were CVRx, Inc. , a Minnesota-based maker of neuromodulation solutions for patients with cardiovascular diseases, that experienced some turbulence in their direct sales team after a management change","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/b6j6Wpey4rnHyMMvD28S2A--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/a2b4e64971b780ade764a8d2ec91aef5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/b6j6Wpey4rnHyMMvD28S2A--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/a2b4e64971b780ade764a8d2ec91aef5"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cvrx-cvrx-declined-due-turbulence-133101139.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CVRX","TISI"],"gpt_icon":0},{"id":"2481353462","title":"CVRx Is Maintained at Buy by Craig-Hallum","url":"https://stock-news.laohu8.com/highlight/detail?id=2481353462","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481353462?lang=en_us&edition=fundamental","pubTime":"2024-11-05 01:36","pubTimestamp":1730741760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CVRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 04, 2024 12:36 ET (17:36 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVRX"],"gpt_icon":0},{"id":"2480058918","title":"BRIEF-CVRX Announces Positive Outpatient Payment For Barostim Procedure In 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2480058918","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480058918?lang=en_us&edition=fundamental","pubTime":"2024-11-04 22:28","pubTimestamp":1730730505,"startTime":"0","endTime":"0","summary":"Nov 4 (Reuters) - CVRx Inc   :   * CVRX ANNOUNCES POSITIVE OUTPATIENT PAYMENT FOR BAROSTIM PROCEDURE IN 2025   * CVRX: APC PAYMENT OF ABOUT $45,000 WILL CONTINUE IN 2025Source text:    Further company coverage:    (Reuters.Briefs@thomsonreuters.com)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","CVRX","BK4539"],"gpt_icon":0},{"id":"2480759586","title":"CVRx (CVRX) Gets a Buy from Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2480759586","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480759586?lang=en_us&edition=fundamental","pubTime":"2024-11-04 22:16","pubTimestamp":1730729777,"startTime":"0","endTime":"0","summary":"In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on CVRx (CVRX – Research Report), with a price target of $19.00...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cvrx-cvrx-gets-a-buy-from-lake-street-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cvrx-cvrx-gets-a-buy-from-lake-street-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","BK4539","CVRX"],"gpt_icon":0},{"id":"2480300023","title":"CVRx announces outpatient payment for Barostim procedure in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2480300023","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480300023?lang=en_us&edition=fundamental","pubTime":"2024-11-04 21:15","pubTimestamp":1730726108,"startTime":"0","endTime":"0","summary":"CVRx (CVRX) announced that the Centers for Medicare and Medicaid Services, CMS, assigned the Barostim procedure to New Technology Ambulatory Paymen...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cvrx-announces-outpatient-payment-for-barostim-procedure-in-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cvrx-announces-outpatient-payment-for-barostim-procedure-in-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","CVRX","BK4082"],"gpt_icon":0},{"id":"2480300853","title":"CVRx Announces Positive Outpatient Payment for Barostim Procedure in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2480300853","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480300853?lang=en_us&edition=fundamental","pubTime":"2024-11-04 21:01","pubTimestamp":1730725310,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241104:nFWN3MB13K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4082","CVRX"],"gpt_icon":0},{"id":"2480300832","title":"CVRx: Apc Payment of About $45,000 Will Continue in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2480300832","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480300832?lang=en_us&edition=fundamental","pubTime":"2024-11-04 21:01","pubTimestamp":1730725310,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241104:nFWN3MB13K:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","BK4539","CVRX"],"gpt_icon":0},{"id":"2480006433","title":"CVRx Announces Positive Outpatient Payment for Barostim Procedure in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2480006433","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480006433?lang=en_us&edition=fundamental","pubTime":"2024-11-04 21:00","pubTimestamp":1730725200,"startTime":"0","endTime":"0","summary":"MINNEAPOLIS, Nov. 04, 2024  -- CVRx, Inc.  , a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services  assigned the Barostim procedure to New Technology Ambulatory Payment Classication  1580. The APC payment of approximately $45,000 will continue in 2025, as published in the 2025 Medicare Hospital Outpatient Prospective Payment System  nal rule.This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements about expected implementation of the Category I CPT code and further facilitation of reimbursement and patient access are forward-looking statements. These statements speak only as of the date of this press release and are based on our current expectations and projections about future events, and are subject to a number of known and unknown risks and uncertainties that could cause actua","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/c4EKzCPjB85tbEvgLPpibw--~B/aD0xMTk7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/19640da9973274de541da7c89cc4851b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/c4EKzCPjB85tbEvgLPpibw--~B/aD0xMTk7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/19640da9973274de541da7c89cc4851b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cvrx-announces-positive-outpatient-payment-130000348.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2237443549.SGD","LU2237443978.SGD","LU2237443382.USD","LU0157215616.USD","LU2420271590.USD","LU2456880835.USD","LU1894683348.USD","BK4082","LU0077335932.USD","BK4208","LU1366192091.USD","CMS","APC","LU2417539215.USD","LU1894683264.USD","BK4585","LU2637428348.USD","BK4588","BK4539","LU1366333091.USD","LU2346227817.USD","LU2237443622.USD","CVRX","LU2236285917.USD"],"gpt_icon":1},{"id":"2480307196","title":"Cantor Fitzgerald Keeps Their Buy Rating on CVRx (CVRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2480307196","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480307196?lang=en_us&edition=fundamental","pubTime":"2024-11-04 20:56","pubTimestamp":1730724980,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Ross Osborn from Cantor Fitzgerald reiterated a Buy rating on CVRx (CVRX – Research Report), with a price target of...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-keeps-their-buy-rating-on-cvrx-cvrx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-keeps-their-buy-rating-on-cvrx-cvrx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CVRX"],"gpt_icon":0},{"id":"2480007423","title":"CVRx, Inc. (NASDAQ:CVRX) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2480007423","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480007423?lang=en_us&edition=fundamental","pubTime":"2024-11-01 19:57","pubTimestamp":1730462263,"startTime":"0","endTime":"0","summary":"Shareholders will be ecstatic, with their stake up 30% over the past week following CVRx, Inc.'s  latest third-quarter results. Revenues were in line with expectations, at US$13m, while statutory losses ballooned to US$0.57 per share. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on CVRx after the latest results.The most important thing to note is the forecast of increased losses next year, suggesting all may not be well at CVRx. Happily, there were no major changes to r","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/oY9vQNBdaHAXW3k6VZJztA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b23fe2923663ce315e2ef7ba313db8b9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/oY9vQNBdaHAXW3k6VZJztA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b23fe2923663ce315e2ef7ba313db8b9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cvrx-inc-nasdaq-cvrx-third-115743177.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B64PRP62.GBP","NDAQ","NQmain","LU2210149790.SGD","IE00BGHQF748.EUR","BK4082","BK4112","BK4539","IE00BKPKM429.USD","IE00B3QW5Z07.USD",".IXIC","SQQQ","QID","TQQQ","BK4585","LU2210150020.SGD","LU2095319765.USD","QLD","MNQmain","PSQ","CVRX","BK4588"],"gpt_icon":1},{"id":"2479731401","title":"CVRx Price Target Raised to $16.00/Share From $13.00 by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2479731401","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479731401?lang=en_us&edition=fundamental","pubTime":"2024-10-31 00:50","pubTimestamp":1730307000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CVRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 30, 2024 12:50 ET (16:50 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVRX"],"gpt_icon":0},{"id":"2479650202","title":"CVRx price target raised to $15 from $12 at Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2479650202","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479650202?lang=en_us&edition=fundamental","pubTime":"2024-10-30 20:48","pubTimestamp":1730292504,"startTime":"0","endTime":"0","summary":"Lake Street raised the firm’s price target on CVRx (CVRX) to $15 from $12 and keeps a Buy rating on the shares. In the “interest of conservatism,” ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cvrx-price-target-raised-to-15-from-12-at-lake-street?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cvrx-price-target-raised-to-15-from-12-at-lake-street?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CVRX"],"gpt_icon":0},{"id":"2479989202","title":"Cantor Fitzgerald Sticks to Their Buy Rating for CVRx (CVRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2479989202","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479989202?lang=en_us&edition=fundamental","pubTime":"2024-10-30 20:46","pubTimestamp":1730292410,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Ross Osborn reiterated a Buy rating on CVRx (CVRX – Research Report) today and set a price target of $14.00. The company’...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-sticks-to-their-buy-rating-for-cvrx-cvrx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-sticks-to-their-buy-rating-for-cvrx-cvrx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CVRX"],"gpt_icon":0},{"id":"2479240151","title":"CVRx Inc (CVRX) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Rising Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2479240151","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479240151?lang=en_us&edition=fundamental","pubTime":"2024-10-30 15:14","pubTimestamp":1730272447,"startTime":"0","endTime":"0","summary":"Total Revenue: $13.4 million, an increase of 27% over Q3 2023.US Revenue: $12.3 million, reflecting 28% growth over the same period last year.Heart Failure Revenue in the US: $12.2 million on 391 revenue units, up from $9.4 million on 303 units in Q3 2023.Active Implanting Centers: 208 centers, up from 159 on September 30, 2023.Sales Territories in the US: 45 territories, up from 35 on September 30, 2023.European Revenue: $1.1 million, a 15% increase compared to the same period last year.Gross Profit: $11.1 million, an increase of $2.3 million compared to Q3 2023.Gross Margin: 83% for Q3 2024, compared to 84% in Q3 2023.Research and Development Expenses: $2.5 million, a decrease of 7% from the same period last year.Net Loss: $13.1 million or $0.57 per share, compared to a net loss of $9 million or $0.43 per share in Q3 2023.Full Year 2024 Revenue Guidance: Expected between $50.5 million and $51.5 million.Q4 2024 Revenue Guidance: Expected between $14.5 million and $15.5 million.GuruFoc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cvrx-inc-cvrx-q3-2024-071407086.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CVRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cvrx.com","stockEarnings":[{"period":"1week","weight":0.12},{"period":"1month","weight":0.0527},{"period":"3month","weight":0.8598},{"period":"6month","weight":0.6675},{"period":"1year","weight":-0.4938},{"period":"ytd","weight":0.12}],"compareEarnings":[{"period":"1week","weight":0.0044},{"period":"1month","weight":-0.0316},{"period":"3month","weight":0.0199},{"period":"6month","weight":0.0578},{"period":"1year","weight":0.2403},{"period":"ytd","weight":0.0044}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.143513},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.143047},{"month":3,"riseRate":0,"avgChangeRate":-0.183992},{"month":4,"riseRate":0.666667,"avgChangeRate":0.046908},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.159837},{"month":6,"riseRate":0.666667,"avgChangeRate":0.308734},{"month":7,"riseRate":0.5,"avgChangeRate":0.012145},{"month":8,"riseRate":0.25,"avgChangeRate":-0.023129},{"month":9,"riseRate":0.25,"avgChangeRate":-0.019364},{"month":10,"riseRate":0.75,"avgChangeRate":0.118494},{"month":11,"riseRate":0.75,"avgChangeRate":0.17744},{"month":12,"riseRate":0.75,"avgChangeRate":0.197628}],"exchange":"NASDAQ","name":"CVRx, Inc.","nameEN":"CVRx, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CVRx, Inc.(CVRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CVRx, Inc.(CVRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CVRx, Inc.,CVRX,CVRx, Inc.股票,CVRx, Inc.股票老虎,CVRx, Inc.股票老虎国际,CVRx, Inc.行情,CVRx, Inc.股票行情,CVRx, Inc.股价,CVRx, Inc.股市,CVRx, Inc.股票价格,CVRx, Inc.股票交易,CVRx, Inc.股票购买,CVRx, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CVRx, Inc.(CVRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CVRx, Inc.(CVRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction